Advice

Following an abbreviated submission:

lacosamide (Vimpat®) is accepted for restricted use within NHS Scotland.

Indication under review: as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.

SMC restriction: patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

SMC has previously accepted lacosamide for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.

Download detailed advice45KB (PDF)

Download

Medicine details

Medicine name:
lacosamide (Vimpat)
SMC ID:
1301/18
Indication:
As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.
Pharmaceutical company
UCB Pharma Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published:
12 February 2018